Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 341.14 Million EUR | -15.04% |
| 2022 | 401.54 Million EUR | -37.92% |
| 2021 | 646.77 Million EUR | 73.98% |
| 2020 | 371.74 Million EUR | 186.9% |
| 2019 | 129.57 Million EUR | 49.41% |
| 2018 | 86.72 Million EUR | -10.3% |
| 2017 | 96.67 Million EUR | -9.51% |
| 2016 | 106.83 Million EUR | -18.36% |
| 2015 | 130.85 Million EUR | 26.95% |
| 2014 | 103.07 Million EUR | -6.54% |
| 2013 | 110.28 Million EUR | 301.41% |
| 2012 | 27.47 Million EUR | -15.83% |
| 2011 | 32.63 Million EUR | -7.31% |
| 2010 | 35.21 Million EUR | 50.31% |
| 2009 | 23.42 Million EUR | 67.7% |
| 2008 | 13.96 Million EUR | 32.1% |
| 2007 | 10.57 Million EUR | 3.03% |
| 2006 | 10.26 Million EUR | 4.48% |
| 2005 | 9.82 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 313.6 Million EUR | -8.07% |
| 2024 Q2 | 300.29 Million EUR | -4.24% |
| 2023 Q2 | 351.86 Million EUR | -8.66% |
| 2023 Q4 | 341.14 Million EUR | -6.03% |
| 2023 FY | 341.14 Million EUR | -15.04% |
| 2023 Q3 | 363.01 Million EUR | 3.17% |
| 2023 Q1 | 385.21 Million EUR | -4.07% |
| 2022 Q2 | 631.85 Million EUR | 0.4% |
| 2022 Q1 | 629.3 Million EUR | -2.7% |
| 2022 Q4 | 401.54 Million EUR | -24.68% |
| 2022 FY | 401.54 Million EUR | -37.92% |
| 2022 Q3 | 533.1 Million EUR | -15.63% |
| 2021 Q2 | 668.03 Million EUR | 28.04% |
| 2021 FY | 646.77 Million EUR | 73.98% |
| 2021 Q1 | 521.75 Million EUR | 40.35% |
| 2021 Q4 | 646.77 Million EUR | 0.0% |
| 2020 Q3 | 373.45 Million EUR | 34.2% |
| 2020 Q4 | 371.74 Million EUR | -0.46% |
| 2020 Q2 | 278.29 Million EUR | 94.04% |
| 2020 Q1 | 143.41 Million EUR | 10.69% |
| 2020 FY | 371.74 Million EUR | 186.9% |
| 2019 FY | 129.57 Million EUR | 49.41% |
| 2019 Q1 | 104.55 Million EUR | 20.56% |
| 2019 Q4 | 129.57 Million EUR | 8.86% |
| 2019 Q3 | 119.02 Million EUR | 1.36% |
| 2019 Q2 | 117.41 Million EUR | 12.3% |
| 2018 FY | 86.72 Million EUR | -10.3% |
| 2018 Q1 | 91.78 Million EUR | -5.06% |
| 2018 Q4 | 86.72 Million EUR | 1.3% |
| 2018 Q3 | 85.61 Million EUR | -4.38% |
| 2018 Q2 | 89.53 Million EUR | -2.45% |
| 2017 Q4 | 96.67 Million EUR | 1.21% |
| 2017 FY | 96.67 Million EUR | -9.51% |
| 2017 Q2 | 100.05 Million EUR | 0.96% |
| 2017 Q1 | 99.1 Million EUR | -7.23% |
| 2017 Q3 | 95.52 Million EUR | -4.54% |
| 2016 Q4 | 106.83 Million EUR | 1.37% |
| 2016 FY | 106.83 Million EUR | -18.36% |
| 2016 Q3 | 105.38 Million EUR | -0.13% |
| 2016 Q2 | 105.51 Million EUR | -1.92% |
| 2016 Q1 | 107.58 Million EUR | -17.78% |
| 2015 Q4 | 130.85 Million EUR | 1.35% |
| 2015 Q1 | 132.19 Million EUR | 28.25% |
| 2015 FY | 130.85 Million EUR | 26.95% |
| 2015 Q2 | 132.11 Million EUR | -0.06% |
| 2015 Q3 | 129.1 Million EUR | -2.28% |
| 2014 Q4 | 103.07 Million EUR | -0.4% |
| 2014 FY | 103.07 Million EUR | -6.54% |
| 2014 Q3 | 103.48 Million EUR | 0.98% |
| 2014 Q2 | 102.47 Million EUR | -1.53% |
| 2014 Q1 | 104.07 Million EUR | -5.63% |
| 2013 Q4 | 110.28 Million EUR | 21.25% |
| 2013 FY | 110.28 Million EUR | 301.41% |
| 2013 Q3 | 90.94 Million EUR | -26.69% |
| 2013 Q2 | 124.06 Million EUR | 0.0% |
| 2013 Q1 | - EUR | -100.0% |
| 2012 FY | 27.47 Million EUR | -15.83% |
| 2012 Q2 | 27.22 Million EUR | 0.0% |
| 2012 Q4 | 27.47 Million EUR | 0.0% |
| 2011 FY | 32.63 Million EUR | -7.31% |
| 2011 Q2 | 37.62 Million EUR | 0.0% |
| 2011 Q4 | 32.63 Million EUR | 0.0% |
| 2010 FY | 35.21 Million EUR | 50.31% |
| 2010 Q2 | 38.03 Million EUR | 0.0% |
| 2010 Q4 | 35.21 Million EUR | 0.0% |
| 2009 Q4 | 23.42 Million EUR | 0.0% |
| 2009 FY | 23.42 Million EUR | 67.7% |
| 2008 FY | 13.96 Million EUR | 32.1% |
| 2007 FY | 10.57 Million EUR | 3.03% |
| 2006 FY | 10.26 Million EUR | 4.48% |
| 2005 FY | 9.82 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -539.985% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -3460.251% |
| SQZ Biotechnologies Company | 50.03 Million USD | -581.756% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -370.732% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -478.073% |
| Mesoblast Limited | 188.44 Million USD | -81.031% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -8757.607% |
| Genus plc | 485 Million USD | 29.661% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -5738.886% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -13457.215% |
| Marizyme, Inc. | 26.67 Million USD | -1178.856% |
| ContraFect Corporation | 32.53 Million USD | -948.674% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -8877.474% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -17118.121% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -8812.627% |
| Intellipharmaceutics International Inc. | 12 Million USD | -2740.791% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -2796.403% |
| MultiCell Technologies, Inc. | 1617.67 USD | -21088502.743% |
| Accustem Sciences Inc. | 1.07 Million USD | -31509.681% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -340.658% |
| EV Biologics, Inc. | 2.11 Million USD | -16029.214% |
| Q BioMed Inc. | 8.13 Million USD | -4094.597% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -311.339% |
| Neon Bloom, Inc. | 1.22 Million USD | -27720.941% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -6529.259% |
| Biomind Labs Inc. | 1.49 Million USD | -22663.998% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | -39.771% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -1753.699% |
| Skye Bioscience, Inc. | 14.07 Million USD | -2324.236% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -16871.241% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -239981.636% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -3503.918% |
| IMV Inc. | 37.93 Million USD | -799.338% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -169525.49% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -5837.254% |
| GB Sciences, Inc. | 5.41 Million USD | -6197.008% |
| Alpha Cognition Inc. | 7.16 Million USD | -4661.406% |
| HST Global, Inc. | 593.59 Thousand USD | -57371.028% |
| CSL Limited | 18.62 Billion USD | 98.168% |
| Halberd Corporation | 728.71 Thousand USD | -46714.204% |
| Enzolytics Inc. | 365.26 Million USD | 6.605% |
| Resverlogix Corp. | 67.39 Million USD | -406.178% |
| Affymax, Inc. | 8.87 Million USD | -3745.609% |
| SYBLEU INC | 681.41 Thousand USD | -49964.205% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -40573.779% |
| argenx SE | 444.95 Million USD | 23.33% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -355.344% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -19803.384% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -2766.009% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -9207.742% |
| AVAX Technologies, Inc. | 3.99 Million USD | -8441.957% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1237318.84% |
| Genscript Biotech Corporation | 1.32 Billion USD | 74.27% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -142845.017% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -9035.406% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -50006.781% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -187.346% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -3672.801% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -509610.29% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -23691.985% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -578.704% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -12480.721% |
| BioStem Technologies, Inc. | 15.9 Million USD | -2044.93% |
| ONE Bio Corp. | 27.49 Million USD | -1140.713% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -73311.821% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1243453.385% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -26992.273% |
| Agentix Corp. | 2.51 Million USD | -13488.39% |
| LadRx Corporation | 2.2 Million USD | -15402.825% |
| Cell Source, Inc. | 15.8 Million USD | -2058.222% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -763153.982% |
| Regen BioPharma, Inc. | 5.45 Million USD | -6150.788% |
| Regen BioPharma, Inc. | 5.45 Million USD | -6150.788% |
| NovAccess Global Inc. | 7.86 Million USD | -4239.85% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1278.581% |
| Itoco Inc. | 1.65 Million USD | -20535.985% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -16528.476% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -5539.676% |
| Kadimastem Ltd | 3.5 Million USD | -9633.436% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -80822.651% |
| CytoDyn Inc. | 127.89 Million USD | -166.74% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -816053.496% |
| Mobile Lads Corp. | 1.31 Million USD | -25872.195% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -21679.176% |
| Qrons Inc. | 1.48 Million USD | -22815.364% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -2988.593% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -42079.344% |
| Rebus Holdings, Inc. | 5.24 Million USD | -6407.898% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -5490.779% |
| International Stem Cell Corporation | 5.27 Million USD | -6364.734% |
| Bioxytran, Inc. | 3.24 Million USD | -10398.354% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -54412.479% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -7288.667% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -732.14% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1432.199% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -16743.398% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -6127.528% |
| Neutra Corp. | 973.52 Thousand USD | -34941.997% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1075.75% |
| PureTech Health plc | 125.58 Million USD | -171.648% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -8979.921% |
| IXICO plc | 1.9 Million USD | -17852.188% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1561.766% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -230.169% |
| CSL Limited | 18.62 Billion USD | 98.168% |
| Cellectis S.A. | 249.36 Million USD | -36.803% |